Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function

Résumé fourni par la source

Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce both systolic blood pressure (SBP) and diastolic blood pressure (DBP), but whether the same is true for the blood pressure lowering effect is unknown. Methods: We performed a systematic literature review in PubMed (Study 1) and analysed data from a clinical study (Study 2) to investigate if the blood pressure lowering effect of SGLT2i depends on baseline eGFR. In the literature review, we performed a weighted regression analysis with mean change in SBP and DBP as dependent variables and mean eGFR as an independent variable. Furthermore, we analyzed data from a cohort of 48 patients with either type 2 diabtes mellitus with and without chronic kidney disease (CKD) or non-diabetic CKD.. Results: For study 1 1645 articles were identified of which 27 articles met the inclusion criteria. Analysis revealed a mean weighted reduction in SBP -4.7 mmHg compared to baseline and -3.5 mmHg compared to placebo. The weighted regression analysis showed no correlation between change in SBP and baseline eGFR. Data analysis of 48 patients (Study 2) revealed a SBP reduction of 5.5 mmHg and the simple linear regression revealed no correlation between the decrease in blood pressure and baseline eGFR. Conclusion: The blood pressure lowering effect of SGLT2i does not depend on baseline eGFR. Funding: Commercial Support - Boehringer-Ingelheim, Government Support – Non-U.S.Difference in systolic blood pressure depending on eGFR (Study 1).Difference in systolic blood pressure depending on eGFR (Study 2).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.